Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer

Table 1 Comparison of the mean percentage of cells staining positive for MMP9 and PCNA among the treatment groups $(\bar{x} \pm SD)$

Group	n	MMP9		PCNA
DMSO	10	0.6312 ± 0.1527		0.9156 ± 0.1022
CoCl₂	10	0.6028 ± 0.1337		0.8833 ± 0.1857
glibenclamide,	10	0.5711 ± 0.1637	F = 324.5 P = 0.00687	0.9017 ± 0.1772	F = 187.6 P = 0.0348
CoCl₂ + glibenclamide	10	0.2856 ± 0.1234		0.5289 ± 0.1403
paclitaxel	10	0.3451 ± 0.1956		0.6574 ± 0.1945

ISSN: 1756-9966